Journal for ImmunoTherapy of Cancer – Page 99

CD47 as a potential predictive biomarker in colorectal cancer

26 de February de 2025 by Stebbing, J., Bullock, A.

In this week’s Journal for ImmunoTherapy for Cancer, Arai and colleagues analyzed next-generation sequencing data for DNA and RNA from 14,287 patients with colorectal cancer (CRC) categorized by median CD47 expression level, and showed that CD47…

Neutrophil extracellular traps impede cancer metastatic seeding via protease-activated receptor 2-mediated downregulation of phagocytic checkpoint CD24

26 de February de 2025 by Liu, Y., Ma, J., Ma, Y., Wang, B.-z., Wang, Y., Yuan, J., Zhang, F., Zhao, X., Chen, K., Zhang, X., Wang, H.

Background
Phagocytic clearance by macrophages represents a critical immune surveillance mechanism in cancer liver metastasis. Neutrophils, the most abundant immune cells encountered by cancer cells in circulation, play key roles in metastasis through…

Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer

26 de February de 2025 by

Background
Antiangiogenics combined with immune checkpoint blockade have become standard of care for recurrent endometrial cancer after standard platinum-based chemotherapy. To dissect mechanisms and define biomarkers associated with clinical outcomes…

Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer

26 de February de 2025 by Zhong, Y., Wang, Y., Wang, C., Cao, K., Wang, X., Xu, X., Yang, M., Zhang, G., Liu, H., Lu, J.

Background
High-grade serous ovarian cancer (HGSOC) is a highly aggressive malignancy marked by an immunosuppressive tumor microenvironment that hinders effective immune responses. A key feature of this environment is the extensive infiltration of mye…

Tumor-specific CD8+ T cells from the bone marrow resist exhaustion and exhibit increased persistence in tumor-bearing hosts as compared with tumor-infiltrating lymphocytes

26 de February de 2025 by Zawidzka, E. M., Biavati, L., Thomas, A., Zanettini, C., Marchionni, L., Leone, R., Borrello, I.

Background
Immunotherapy is now an integral aspect of cancer therapy. Strategies employing adoptive cell therapy (ACT) have seen the establishment of chimeric antigen receptor (CAR)-T cells using peripheral blood lymphocytes as well as tumor-infiltrat…

Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma

26 de February de 2025 by Zhang, P., Wang, D., Zhou, G., Jiang, S., Zhang, G., Zhang, L., Zhang, Z.

Background
Lung adenocarcinoma (LUAD) presents significant challenges in prognosis and treatment efficacy evaluation. While post-translational modifications are known to influence tumor progression, their prognostic value in LUAD remains largely unexp…

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

26 de February de 2025 by

Background
Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone r…

Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer

26 de February de 2025 by Li, L., Zhao, L., Zhou, D., Yu, Y., Zhang, P., Zheng, J., Lin, Z., Yu, D., Ren, J., Zhang, J., Zhou, P., Zhang, D., Zhang, T.

Background
Despite advancements in treatment modalities, several patients with colorectal cancer (CRC) remain unresponsive to immune checkpoint inhibitor therapy. Pyroptosis, an inflammatory programmed cell death process, holds substantial promise for…

Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fc{gamma} receptor-mediated modulation of the tumor microenvironment

26 de February de 2025 by Son, W., Lee, Y., Park, Y., Park, K.-S., Kim, S., Youn, H., Seo, A., Sung, B., Lee, S. H., Won, J.

Background
TIGIT was identified as a target immune checkpoint for overcoming resistance to PD-(L)1-blocking antibodies. However, the clinical efficacies of TIGIT antibodies were moderate in monotherapy and mixed in combination with PD-(L)1 antibodies….

Disruption of GPSM1/CSF1 signaling reprograms tumor-associated macrophages to overcome anti-PD-1 resistance in colorectal cancer

26 de February de 2025 by Chen, Y., Jia, H., Zhang, X., Zhao, H., Xiao, Y., Li, N., Yao, Y., Xing, X.

Background
Immune checkpoint blockade (ICB) therapies, particularly anti-PD-1, benefit only a limited subset of colorectal cancer (CRC) patients. G-protein signaling modulator 1 (GPSM1) is implicated in immunity and oncology, yet its role in regulatin…